Heska's Hematology Analyzer Selected by VetSmart as

Equipment of Choice FORT COLLINS, Colo. (PROTEXT) - Heska Corporation (Nasdaq:HSKA), today announced that VetSmart Pet Hospitals and HealthCenters, a leading provider of veterinary services, has selectedthe HESKA(TM) Vet ABC-Diff Hematology Analyzer as the hematologyanalyzer of choice for use in its veterinary hospitals andwellness clinics. The Vet ABC-Diff Hematology Analyzer is a convenient and easy-to-use tabletop blood cell counter which provides crucialclinical information to the veterinarian in less than twominutes. This information includes the results of 16 differentblood parameters with the accuracy of more expensive referencelaboratory equipment. Heska is the exclusive North Americandistributor for the Vet ABC-Diff unit, which is provided by ScilGmbH, a former subsidiary of Boehringer Mannheim GmbH. The diagnostic instrument's potential has been recognized byone of the largest multiple-location veterinary practices in theworld. "VetSmart's focus on high quality, convenient andaffordable medicine has enabled us to grow to over 385 locationsin 37 states throughout the country," said Scott Campbell, DVMand Don Spear, Senior Partners at VetSmart. "When making aninvestment of this magnitude, we considered every hematologyanalyzer on the market today. We chose Heska's Vet ABC-Diff unitbecause it was the best unit to give our partner doctors avaluable tool to continue treating pets like family. We believeHeska is also uniquely qualified to supply us with the after-sales service and technical consultation to continually keep ourhospitals on the leading edge of hematology practice." Jim Fuller, President and Chief Operating Officer of HeskaCorporation, said, "We are especially pleased with VetSmart'sdecision to adopt our Vet ABC-Diff unit as their hematologyinstrument of choice. We believe this represents the start of along-term relationship with VetSmart and demonstrates theirstrong support of our company and our products." Heska discovers, develops, manufactures and markets companionanimal health products, primarily for dogs, cats and horses.Heska has a large and sophisticated scientific effort devoted toapplying biotechnology to the large and growing companion animalhealth market. Heska also offers diagnostic and patientmonitoring equipment and supplies, as well as laboratorydiagnostic products in the United States and Europe toveterinarians, and operates USDA- and FDA-licensed facilitieswhich manufacture vaccine, pharmaceutical, and allergyimmunotherapy products. For additional information on Heska andits products, visit the company's web site at www.heska.com. Except for the historical information contained herein, thematters set forth in this press release, such as statements as tomarket acceptance of Heska's products and services, and therelationship with VetSmart are forward- looking statements thatare subject to risks and uncertainties. Such forward- lookingstatements involve known and unknown risks, uncertainties andother factors which may cause actual results, performance orachievements of Heska to be materially different from any futureresults, performance or achievements expressed or implied by suchforward-looking statements. Heska's achievement of these resultsmay be affected by many factors, including among others, thefollowing: delays in or failure to achieve market acceptance ofproducts; delays in or failure to achieve future productdevelopment; uncertainties regarding the outcome of research anddevelopment efforts or the ability to successfully develop orcommercialize products in research and development, uncertaintiesregarding the ability to receive required regulatory approvals ina timely manner, if at all, uncertainties regarding the scope,enforceability and validity of patents and proprietary rights;competition; inability to obtain renewal or continuation ofcontracts, or obtain exclusivity, to market, sell or distributeproducts described herein; inability to manufacture, market, sellor distribute products at currently projected costs and the risksset forth in Heska's filings and future filings with theSecurities and Exchange Commission, including those set forth inHeska's Quarterly Report on Form 10-Q for the quarter ended March31, 1999. ots Original Text Service: Heska Corporation Internet:http://www.newsaktuell.de Contact: Ron Hendrick, Executive VicePresident & Chief Financial Officer of Heska Corporation, 970-493-7272, ext. 4105; or Matthew Knight, 212-696-4455 ext. 271(Media), or Ana Kapor, 415-677-4455 ext. 207, both ofNoonan/Russo Communications Inc. for Heska Corporation Web site:http://www.heska.com

Subscribers please note that material bearing the slug"PROTEXT" is not part of CTK's news service and is not to bepublished under the "CTK" slug. Protext is a commercial serviceproviding distribution of press releases from clients, who areidentified in the text of Protext reports and who bear fullresponsibility for their contents.

PROTEXT